Was können GLP-1-Rezeptor-Agonisten bei Adipositas leisten?
Robert Stein(Cleveland Clinic), Antje Körner(IFB Adiposity Diseases), E. Wenzel(Helmholtz Munich), Roland Pfäffle(Leipzig University)
Cited by 0
Related Papers
Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
|Cell Metabolism|2007|899
Nampt: linking NAD biology, metabolism and cancer
|Trends in Endocrinology and Metabolism|2008|399
The LIFE-Adult-Study: objectives and design of a population-based cohort study with 10,000 deeply phenotyped adults in Germany
|BMC Public Health|2015|374